

Resource Summary Report

Generated by [ASWG](#) on Aug 15, 2026

CD3 Monoclonal Antibody (F7.2.38)

RRID:AB_10979571

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# MA5-12577, RRID:AB_10979571

Antibody Information

URL: http://antibodyregistry.org/AB_10979571

Proper Citation: Thermo Fisher Scientific Cat# MA5-12577, RRID:AB_10979571

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2024; Applications: ICC/IF (1:250), WB (1:250-1:1,000), IHC (P) (1:100), IHC (1:100-1:250)

Antibody Name: CD3 Monoclonal Antibody (F7.2.38)

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone F7.2.38

Defining Citation: [PMID:19220831](#)

Antibody ID: AB_10979571

Vendor: Thermo Fisher Scientific

Catalog Number: MA5-12577

Record Creation Time: 20250820T005727+0000

Record Last Update: 20250820T093852+0000

Ratings and Alerts

No rating or validation information has been found for CD3 Monoclonal Antibody (F7.2.38).

No alerts have been found for CD3 Monoclonal Antibody (F7.2.38).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Wenning AS, et al. (2026) RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged Survival in Pancreatic Adenocarcinoma. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*, 39(7), 101010.

Shen Y, et al. (2026) comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders. *Cell stem cell*, 33(3), 421.

Reinhold A, et al. (2025) Ionizing radiation and photodynamic therapy lead to multimodal tumor cell death, synergistic cytotoxicity and immune cell invasion in human bladder cancer organoids. *Photodiagnosis and photodynamic therapy*, 51, 104459.

Liang Z, et al. (2024) Intestinal CXCR6+ ILC3s migrate to the kidney and exacerbate renal fibrosis via IL-23 receptor signaling enhanced by PD-1 expression. *Immunity*, 57(6), 1306.

Karamitopoulou E, et al. (2024) Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(18), 4215.